Morgan Stanley Lipocine Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.3 - $0.58 $0 - $0	-1 Reduced -0.0%	23,481 $7,000
Q4 2022 Feb 14, 2023	SELL	$0.37 - $8.65 $4,460 - $104,275	-12,055 Reduced 33.92%	23,482 $9,000
Q3 2022 Nov 14, 2022	SELL	$0.49 - $7.65 $10,510 - $164,092	-21,450 Reduced 37.64%	35,537 $16,000
Q2 2022 Oct 27, 2022	BUY	$0.73 - $1.34 $11,799 - $21,659	16,164 Added 39.6%	56,987 $45,000
Q2 2022 Aug 15, 2022	BUY	$0.73 - $1.34 $11,799 - $21,659	16,164 Added 39.6%	56,987 $45,000
Q1 2022 Oct 27, 2022	SELL	$0.89 - $1.85 $14,385 - $29,903	-16,164 Reduced 28.36%	40,823 $55,000
Q1 2022 May 13, 2022	SELL	$0.89 - $1.85 $165,028 - $343,036	-185,425 Reduced 81.96%	40,823 $55,000
Q4 2021 Feb 14, 2022	SELL	$0.99 - $1.2 $193,020 - $233,964	-194,970 Reduced 46.29%	226,248 $224,000
Q3 2021 Nov 15, 2021	BUY	$1.08 - $1.49 $454,915 - $627,614	421,218 New	421,218 $459,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $434M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.